EGFR and non-small cell lung carcinoma: We report the first evidence that M-COPA has a preferential antitumor effect on NSCLC cells harboring activating L858R and del19 mutations, but also those with a T790M/del19 double mutation and C797S/T790M/del19 triple mutation, which exhibit resistance to first- and third-generation EGFR-TKIs, respectively.